Jeffrey R Curtis1, Aseem Bharat2, Lang Chen2, Jeffrey D Greenberg2, Leslie Harrold2, Joel M Kremer2, Tanya Sommers2, Dimitrios Pappas2. 1. From the University of Alabama at Birmingham, Birmingham, Alabama; Consortium of Rheumatology Researchers of North America (CORRONA) LLC, Southborough; University of Massachusetts, Worcester, Massachusetts, USA.J.R. Curtis, MD, MS, MPH, University of Alabama at Birmingham; A. Bharat, MD, MPH, University of Alabama at Birmingham; L. Chen, PhD, University of Alabama at Birmingham; J.D. Greenberg, MD, MPH, CORRONA LLC; L. Harrold, MD, MPH, University of Massachusetts; J.M. Kremer, MD, CORRONA LLC; T. Sommers, MS, CORRONA LLC; D. Pappas, MD, MPH, CORRONA LLC. jrcurtis@uabmc.edu. 2. From the University of Alabama at Birmingham, Birmingham, Alabama; Consortium of Rheumatology Researchers of North America (CORRONA) LLC, Southborough; University of Massachusetts, Worcester, Massachusetts, USA.J.R. Curtis, MD, MS, MPH, University of Alabama at Birmingham; A. Bharat, MD, MPH, University of Alabama at Birmingham; L. Chen, PhD, University of Alabama at Birmingham; J.D. Greenberg, MD, MPH, CORRONA LLC; L. Harrold, MD, MPH, University of Massachusetts; J.M. Kremer, MD, CORRONA LLC; T. Sommers, MS, CORRONA LLC; D. Pappas, MD, MPH, CORRONA LLC.
Abstract
OBJECTIVE: Rheumatologists have limited tools to assess medication adherence. The extent to which methotrexate (MTX) adherence is overestimated by rheumatologists is unknown. METHODS: We deployed an Internet survey to patients with rheumatoid arthritis (RA) participating in a US registry. Patient self-report was the gold standard compared to MTX recorded in the registry. RESULTS: Response rate to the survey was 44%. Of 228 patients whose rheumatologist reported current MTX at the time of the most recent registry visit, 45 (19.7%) had discontinued (n = 19, 8.3%) or missed ≥ 1 dose in the last month (n = 26, 11.4%). For the subgroup whose rheumatologist also confirmed at the next visit that they were still taking MTX (n = 149), only 2.6% reported not taking it, and 10.7% had missed at least 1 dose. CONCLUSION: MTX use was misclassified for 13%-20% of patients, mainly because of 1 or more missed doses rather than overt discontinuation. Clinicians should be aware of suboptimal adherence when assessing MTX response.
OBJECTIVE: Rheumatologists have limited tools to assess medication adherence. The extent to which methotrexate (MTX) adherence is overestimated by rheumatologists is unknown. METHODS: We deployed an Internet survey to patients with rheumatoid arthritis (RA) participating in a US registry. Patient self-report was the gold standard compared to MTX recorded in the registry. RESULTS: Response rate to the survey was 44%. Of 228 patients whose rheumatologist reported current MTX at the time of the most recent registry visit, 45 (19.7%) had discontinued (n = 19, 8.3%) or missed ≥ 1 dose in the last month (n = 26, 11.4%). For the subgroup whose rheumatologist also confirmed at the next visit that they were still taking MTX (n = 149), only 2.6% reported not taking it, and 10.7% had missed at least 1 dose. CONCLUSION:MTX use was misclassified for 13%-20% of patients, mainly because of 1 or more missed doses rather than overt discontinuation. Clinicians should be aware of suboptimal adherence when assessing MTX response.
Authors: Jeffrey R Curtis; Andrew O Westfall; Jeroan Allison; Allison Freeman; Stacey H Kovac; Kenneth G Saag Journal: Pharmacoepidemiol Drug Saf Date: 2006-10 Impact factor: 2.890
Authors: Grant W Cannon; Ted R Mikuls; Candace L Hayden; Jian Ying; Jeffrey R Curtis; Andreas M Reimold; Liron Caplan; Gail S Kerr; J Steuart Richards; Dannette S Johnson; Brian C Sauer Journal: Arthritis Care Res (Hoboken) Date: 2011-12 Impact factor: 4.794
Authors: Emma Dures; Celia Almeida; Judy Caesley; Alice Peterson; Nicholas Ambler; Marianne Morris; Jon Pollock; Sarah Hewlett Journal: Ann Rheum Dis Date: 2014-09-26 Impact factor: 19.103
Authors: Christian A Waimann; Maria F Marengo; Sofia de Achaval; Vanessa L Cox; Araceli Garcia-Gonzalez; John D Reveille; Marsha N Richardson; Maria E Suarez-Almazor Journal: Arthritis Rheum Date: 2013-06
Authors: Dimitrios A Pappas; Joel M Kremer; George Reed; Jeffrey D Greenberg; Jeffrey R Curtis Journal: BMC Musculoskelet Disord Date: 2014-04-01 Impact factor: 2.362
Authors: Frank Behrens; Michaela Koehm; Tanja Rossmanith; Rieke Alten; Martin Aringer; Marina Backhaus; Gerd R Burmester; Eugen Feist; Eva Herrmann; Herbert Kellner; Klaus Krueger; Annette Lehn; Ulf Müller-Ladner; Andrea Rubbert-Roth; Hans-Peter Tony; Siegfried Wassenberg; Harald Burkhardt Journal: Rheumatology (Oxford) Date: 2021-11-03 Impact factor: 7.580